Catalogue No.
21062326
97-7
97-7
Cell Line Name
97-7
Cell Line Description
Cell line 97-7 was established from a transitional cell carcinoma (TCC) in the bladder (Stage T1, Grade II/III). The patient had 2 recurrences before it was terminal - patient died from metastatic bladder cancer.
This TCC had low levels of p16/CDKN2A (a tumor-supressor gene and its protein product p16INK4A, the second most common alteration found across all human cancer types, including bladder cancer) and was classified as -p16 (based on depositor functional studies). It also showed low levels of wild-type pRb (retinoblastoma protein) encoded by the RB1 tumor-supressor gene, (immunoprecipitation studies revealed that pRb exists primarily in the hyperphosphorylated state), and the levels of E2F-1 were relatively low.
General Info
Species
Human
Unique to ECACC
Yes
Also Known As
TCC 97-7
Links
Release Conditions
Characteristics
Products
The line was deposited with a full STR profile from the depositor along with the following cell line mutation data: FGFR31 - p.S249C, PIK3CA - WT, PIK3R1 - WT, TP53 - p.M40I; p.A74fs, RAS - WT, TSC1 - WT, AKT1 - WT, STAG2 - WT, TERT promoter - -124 bp G>A, CDKN2A copy number - Retained.
Tissue of Origin
Transitional cell carcinoma (TCC) in the bladder
DNA profile (STR Profile)
Amelogenin: X, Y
CSF1PO: 10, 11
D3S1358: 16,16
D5S818: 12, 12
D7S820: 10, 10
D8S1179: 11, 11
D13S317: 12, 13
D16S539: 11, 13
D18S51: 13, 13
FGA: 20, 20
Penta D: 12, 12
Penta E: 10, 13
TH01: 7, 9.3
TPOX: 8, 8
vWA: 17, 18
Disease
Transitional cell carcinoma
Culture Conditions
Subculture Routine
Incubate cells at 37oC with 5% CO2.
Split sub-confluent log-phase cultures with 0.05% Trypsin/EDTA solution. Neutralise trypsin/EDTA solution with media containing 10% Foetal Bovine serum (FBS) or Soya bean trypsin inhibitor (SBTI) solution at ratio of 1:10, for low serum cultures.
Establish new cultures at 1-4 x 104 cells per cm2.
Cell lines are relatively slow growing under these culture conditions.
Culture Medium
Hams F-12 + 1% Foetal Bovine Serum (FBS) + 1x Insulin-Transferrin-Selenium + 1μg/ml hydrocortisone + 1x Non-essential amino acids 100x + 2mM L-Glutamine
Cryopreserve cells in standard freeze mix (90% Foetal Bovine Serum (FBS) + 10% DMSO)
Growth Mode
Adherent
Additional Info
Depositor
Deposited by Margaret Knowles at the Division of Molecular Medicine, Leeds Institute of Medical Research at St James’s, St James's University Hospital. Originator: Dr Catherine Reznikoff Departments of Human Oncology, University of Wisconsin Comprehensive Cancer Centre and University of Wisconsin Medical School.
Country of Origin
United States
Hazard Group (ACDP)
Hazard Group (ACDP) 2
Applications
References
Yeager, T R et al. “Overcoming cellular senescence in human cancer pathogenesis.” Genes & development vol. 12,2 (1998): 163-74. doi:10.1101/gad.12.2.163 PMID: 9436977
Sarkar, S et al. “Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.” Cancer research vol. 60,14 (2000): 3862-71. PMID: 10919661
Bibliography
Taylor, Claire F et al. “Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes.” Human molecular genetics vol. 23,8 (2014): 1964-74. doi:10.1093/hmg/ddt589 PMID: 24270882
Platt, Fiona M et al. “Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research vol. 15,19 (2009): 6008-17. doi:10.1158/1078-0432.CCR-09-0898 PMID: 19789314
Jebar, Adel H et al. “FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.” Oncogene vol. 24,33 (2005): 5218-25. doi:10.1038/sj.onc.1208705 PMID: 15897885
Aveyard, Joanne S, and Margaret A Knowles. “Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.” The Journal of molecular diagnostics : JMD vol. 6,4 (2004): 356-65. doi:10.1016/S1525-1578(10)60532-6 PMID: 15507675
Ross, Rebecca L et al. “Identification of mutations in distinct regions of p85 alpha in urothelial cancer.” PloS one vol. 8,12 e84411. 18 Dec. 2013, doi:10.1371/journal.pone.0084411 PMID: 24367658
Askham, J M et al. “AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.” Oncogene vol. 29,1 (2010): 150-5. doi:10.1038/onc.2009.315 PMID: 19802009
Available Formats
- Frozen
- DNA-5µg (100ng/µl)
Citation Guidance
If use of this culture results in a scientific publication, it should be cited in the publication as: 97-7 (ECACC 21062326).
Biosafety Information
Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Further Information
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.